Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Alzheimer's Disease

Free Subscription Articles published in BMJ Retrieve available abstracts of 28 articles: HTML format

Single Articles

September 2025
1. NOGRADY B
   Lecanamab: Controversial Alzheimer's drug approved by Australian drugs regulator after two rejections.
   BMJ. 2025;390:r2056.
   PubMed    
   
   
   
2. BOWIE K
   Alzheimer's blood test could open door to new drugs on the NHS, researchers say.
   BMJ. 2025;390:r1916.
   PubMed    
   
   
   
3. DYER O
   Injectable Alzheimer's drug lecanemab approved in US for use at home.
   BMJ. 2025;390:r1888.
   PubMed    
   
   
   August 2025
4. VAN GOOL WA, Siebrand JAF, Brayne C, Larson EB, et al
   Evidence gap in blood biomarkers for Alzheimer's disease.
   BMJ. 2025;390:e084781.
   PubMed    
   
   
   June 2025
5. IACOBUCCI G
   Benefits of Alzheimer's drugs remain too small to justify costs, says NICE.
   BMJ. 2025;389:r1270.
   PubMed    
   
   
   
6. MAHASE E
   Alzheimer's disease: Rise in new drugs being trialled sparks hope among experts.
   BMJ. 2025;389:r1148.
   PubMed    
   
   
   May 2025
7. TANNE JH
   FDA approves blood test to diagnose Alzheimer's.
   BMJ. 2025;389:r1082.
   PubMed    
   
   
   April 2025
8. BAKCHINE S, Colosimo C, Emilsson E, Jonsdottir SE, et al
   Concerns about the approval of lecanemab for Alzheimer's disease.
   BMJ. 2025;389:r778.
   PubMed    
   
   
   
9. IACOBUCCI G
   Lecanemab: Experts criticise European Commission approval of Alzheimer's drug.
   BMJ. 2025;389:r796.
   PubMed    
   
   
   March 2025
10. MAHASE E
    Lecanemab and donanemab: NICE reconsiders controversial Alzheimer's drugs.
    BMJ. 2025;388:r463.
    PubMed    
    
    
    
11. WISE J
    Lecanemab: European drug agency upholds decision to recommend Alzheimer's drug.
    BMJ. 2025;388:r439.
    PubMed    
    
    
    December 2024
12. R PATEL V, Liu M, Worsham CM, Jena AB, et al
    Alzheimer's disease mortality among taxi and ambulance drivers: population based cross sectional study.
    BMJ. 2024;387:e082194.
    PubMed     Abstract available
    
    
    November 2024
13. MAHASE E
    Alzheimer's disease: What treatments could be rolled out in the next few years?
    BMJ. 2024;387:q2477.
    PubMed    
    
    
    October 2024
14. MAHASE E
    NICE rejects Alzheimer's drug donanemab owing to cost and "significant health risks".
    BMJ. 2024;387:q2342.
    PubMed    
    
    
    September 2024
15. LENZER J, Brownlee S
    Donanemab: Conflicts of interest found in FDA committee that approved new Alzheimer's drug.
    BMJ. 2024;386:q2010.
    PubMed    
    
    
    August 2024
16. KMIETOWICZ Z, Mahase E
    Lecanemab: Benefits of Alzheimer's drug are "just too small" to justify cost, says NICE.
    BMJ. 2024;386:q1853.
    PubMed    
    
    
    July 2024
17. MAHASE E
    Lecanemab: European drug agency rejects Alzheimer's drug amid debate over efficacy and safety.
    BMJ. 2024;386:q1692.
    PubMed    
    
    
    
18. DYER O
    Scientist who worked on Cassava's Alzheimer drug simufilam charged with fraud.
    BMJ. 2024;386:q1568.
    PubMed    
    
    
    June 2024
19. DYER O
    Donanemab: FDA experts recommend approval of Alzheimer's drug.
    BMJ. 2024;385:q1327.
    PubMed    
    
    
    May 2024
20. NOLAN T
    A potential new treatment for Alzheimer's disease ... and other research.
    BMJ. 2024;385:q1125.
    PubMed    
    
    
    February 2024
21. IACOBUCCI G
    Sixty seconds on . . . Viagra and Alzheimer's disease.
    BMJ. 2024;384:q370.
    PubMed    
    
    
    
22. DYER O
    Aduhelm: Biogen abandons Alzheimer's drug after controversial approval left it unfunded by Medicare.
    BMJ. 2024;384:q281.
    PubMed    
    
    
    October 2023
23. DALY TP
    Informing consent to antibodies in Alzheimer's disease.
    BMJ. 2023;383:p2350.
    PubMed    
    
    
    August 2023
24. HOWARD R, Kales HC
    New treatments for Alzheimer's disease.
    BMJ. 2023;382:1852.
    PubMed    
    
    
    July 2023
25. IACOBUCCI G
    Donanemab leads to modest slowing of Alzheimer's progression, study finds.
    BMJ. 2023;382:p1659.
    PubMed    
    
    
    
26. MAHASE E
    Alzheimer's disease: Lecanemab gets full FDA approval and black box safety warning.
    BMJ. 2023;382:p1580.
    PubMed    
    
    
    June 2023
27. POURHADI N, Morch LS, Holm EA, Torp-Pedersen C, et al
    Menopausal hormone therapy and dementia: nationwide, nested case-control study.
    BMJ. 2023;381:e072770.
    PubMed     Abstract available
    
    
    March 2023
28. TANNE JH
    Lecanemab: US Veterans Health Administration will cover cost of new Alzheimer's drug.
    BMJ. 2023;380:p628.
    PubMed    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Alzheimer's Disease is free of charge.